Corcept Therapeutics is trading at $75.00 (-8.46%) in after-hours trading following its Q3 earnings release; available sources do not establish which result drove the decline.
- Third-quarter revenue was $340.5 million, up 64% year over year, including $91.4 million from Lifyorli.
- The company reiterated 2026 revenue guidance of $1.1–$1.2 billion rather than raising it.